DE102007026341A1
(de)
|
2007-06-06 |
2008-12-11 |
Merck Patent Gmbh |
Benzoxazolonderivate
|
DE102007032507A1
(de)
|
2007-07-12 |
2009-04-02 |
Merck Patent Gmbh |
Pyridazinonderivate
|
DE102007061963A1
(de)
|
2007-12-21 |
2009-06-25 |
Merck Patent Gmbh |
Pyridazinonderivate
|
WO2009099982A1
(en)
|
2008-02-04 |
2009-08-13 |
Osi Pharmaceuticals, Inc. |
2-aminopyridine kinase inhibitors
|
AR070317A1
(es)
|
2008-02-06 |
2010-03-31 |
Osi Pharm Inc |
Furo (3,2-c) piridina y tieno (3,2-c) piridinas
|
EP2247600A4
(de)
*
|
2008-02-06 |
2011-09-14 |
Biomarin Pharm Inc |
Benzoxazolcarbonsäureamide als inhibitoren von poly(adp-ribose)polymerase (parp)
|
DE102008019907A1
(de)
|
2008-04-21 |
2009-10-22 |
Merck Patent Gmbh |
Pyridazinonderivate
|
DE102008028905A1
(de)
|
2008-06-18 |
2009-12-24 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
|
MX2011004953A
(es)
|
2008-11-10 |
2011-12-14 |
Vertex Pharma |
Compuestos utiles como inhibidores de cinasa atr.
|
TWI396689B
(zh)
|
2008-11-14 |
2013-05-21 |
Amgen Inc |
作為磷酸二酯酶10抑制劑之吡衍生物
|
KR101716514B1
(ko)
*
|
2008-12-02 |
2017-03-14 |
이 아이 듀폰 디 네모아 앤드 캄파니 |
살진균제 복소환 화합물
|
CN102300862B
(zh)
|
2008-12-19 |
2016-11-23 |
沃泰克斯药物股份有限公司 |
用作atr激酶抑制剂的化合物
|
PE20120016A1
(es)
|
2008-12-22 |
2012-01-24 |
Merck Patent Gmbh |
Nuevas formas polimorficas de dihidrogeno-fosfato de 6-(1-metil-1h-pirazol-4-il)-2-{3-[5-(2-morfolin-4-il-etoxi)-pirimidin-2-il]-bencil}-2h-piridazin-3-ona y procesos para su preparacion
|
DE102009033208A1
(de)
*
|
2009-07-15 |
2011-01-20 |
Merck Patent Gmbh |
Aminopyridinderivate
|
AR078984A1
(es)
*
|
2009-11-13 |
2011-12-14 |
Astrazeneca Ab |
Pirazina sustituida con oxazolo (4,5-c) piridina
|
EP2569287B1
(de)
|
2010-05-12 |
2014-07-09 |
Vertex Pharmaceuticals Inc. |
Verbindungen als hemmer der atr-kinase
|
US8969356B2
(en)
|
2010-05-12 |
2015-03-03 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
NZ603477A
(en)
*
|
2010-05-12 |
2014-09-26 |
Vertex Pharma |
Compounds useful as inhibitors of atr kinase
|
JP5856151B2
(ja)
*
|
2010-05-12 |
2016-02-09 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
Atrキナーゼ阻害剤として有用な2−アミノピリジン誘導体
|
US8962631B2
(en)
|
2010-05-12 |
2015-02-24 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
EP2569286B1
(de)
|
2010-05-12 |
2014-08-20 |
Vertex Pharmaceuticals Inc. |
Verbindungen als hemmer der atr-kinase
|
UY33452A
(es)
|
2010-06-16 |
2012-01-31 |
Bayer Schering Pharma Ag |
Triazolopiridinas sustituidas
|
JP2013529643A
(ja)
|
2010-06-23 |
2013-07-22 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Atrキナーゼ阻害剤として有用なピロロピラジン誘導体
|
WO2012003338A1
(en)
|
2010-07-01 |
2012-01-05 |
Takeda Pharmaceutical Company Limited |
COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
|
US8754114B2
(en)
|
2010-12-22 |
2014-06-17 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
|
WO2012121939A2
(en)
*
|
2011-03-04 |
2012-09-13 |
Locus Pharmaceuticals, Inc. |
Aminopyrazine compounds
|
CN102718745A
(zh)
*
|
2011-03-30 |
2012-10-10 |
中国科学院上海药物研究所 |
新型胺基吡啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途
|
CN103562204A
(zh)
|
2011-04-05 |
2014-02-05 |
沃泰克斯药物股份有限公司 |
可用作tra激酶的抑制剂的氨基吡嗪化合物
|
WO2012138809A1
(en)
*
|
2011-04-05 |
2012-10-11 |
Dawei Zhang |
Heterocyclic compounds as kinase inhibitors
|
ES2699256T3
(es)
|
2011-05-23 |
2019-02-08 |
Merck Patent Gmbh |
Piridina y derivados de pirazina
|
LT2714668T
(lt)
|
2011-05-23 |
2017-04-10 |
Merck Patent Gmbh |
Tiazolo dariniai
|
EP2723747A1
(de)
|
2011-06-22 |
2014-04-30 |
Vertex Pharmaceuticals Inc. |
Als art-kinasehemmer nützliche verbindungen
|
JP2014520161A
(ja)
|
2011-06-22 |
2014-08-21 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Atrキナーゼ阻害剤として有用な化合物
|
US9309250B2
(en)
|
2011-06-22 |
2016-04-12 |
Vertex Pharmaceuticals Incorporated |
Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
|
CA2842841C
(en)
*
|
2011-07-27 |
2016-04-19 |
Nanjing Allgen Pharma Co. Ltd. |
Spirocyclic molecules as protein kinase inhibitors
|
DE102011112978A1
(de)
|
2011-09-09 |
2013-03-14 |
Merck Patent Gmbh |
Benzonitrilderivate
|
EP2940017B1
(de)
|
2011-09-30 |
2019-08-28 |
Vertex Pharmaceuticals Incorporated |
Verfahren zur Herstellung von als Hemmer der ATR-Kinase nützlichen Verbindungen
|
MX2014003785A
(es)
|
2011-09-30 |
2014-07-24 |
Vertex Phamaceuticals Inc |
Tratamiento del cancer de pancreas y del cancer de pulmon de celulas no pequeñas con inhibidores de atr.
|
EP2751088B1
(de)
|
2011-09-30 |
2016-04-13 |
Vertex Pharmaceuticals Incorporated |
Als atr-kinasehemmer nützliche verbindungen
|
JP2014528419A
(ja)
|
2011-09-30 |
2014-10-27 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
Atrキナーゼ阻害剤として有用な化合物
|
US8853217B2
(en)
|
2011-09-30 |
2014-10-07 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
CN103087050A
(zh)
*
|
2011-10-28 |
2013-05-08 |
山东轩竹医药科技有限公司 |
芳基激酶抑制剂
|
EP2776429A1
(de)
|
2011-11-09 |
2014-09-17 |
Vertex Pharmaceuticals Incorporated |
Als atr-kinaseinhibitoren nützliche verbindungen
|
WO2013071093A1
(en)
|
2011-11-09 |
2013-05-16 |
Vertex Pharmaceuticals Incorporated |
Pyrazine compounds useful as inhibitors of atr kinase
|
EP2776422A1
(de)
|
2011-11-09 |
2014-09-17 |
Vertex Pharmaceuticals Incorporated |
Als atr-kinasehemmer nützliche verbindungen
|
US8841449B2
(en)
|
2011-11-09 |
2014-09-23 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
WO2013071088A1
(en)
|
2011-11-09 |
2013-05-16 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
DE102011119127A1
(de)
|
2011-11-22 |
2013-05-23 |
Merck Patent Gmbh |
3-Cyanaryl-1H-pyrrolo[2.3-b]pyridin-Derivate
|
JP6006241B2
(ja)
*
|
2012-01-31 |
2016-10-12 |
第一三共株式会社 |
ピリドン誘導体
|
EP2812337B1
(de)
|
2012-02-09 |
2016-09-07 |
Merck Patent GmbH |
Furo-[3,2-b-]pyridinderivate als tbk1- und ikk-hemmer
|
WO2013148537A1
(en)
*
|
2012-03-29 |
2013-10-03 |
Ning Xi |
Substituted spirobicyclic compounds and methods of use
|
NZ720511A
(en)
|
2012-04-05 |
2016-12-23 |
Vertex Pharma |
Compounds useful as inhibitors of atr kinase and combination therapies thereof
|
US9096579B2
(en)
|
2012-04-20 |
2015-08-04 |
Boehringer Ingelheim International Gmbh |
Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments
|
WO2013162061A1
(ja)
*
|
2012-04-26 |
2013-10-31 |
第一三共株式会社 |
二環性ピリミジン化合物
|
ES2704744T3
(es)
|
2012-06-13 |
2019-03-19 |
Incyte Holdings Corp |
Compuestos tricíclicos sustituidos como inhibidores de FGFR
|
KR101245559B1
(ko)
*
|
2012-06-29 |
2013-03-22 |
한국화학연구원 |
신규 다중치환 벤즈옥사졸로 치환된 피리딘 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 이상세포 성장 질환의 예방 및 치료용 약학적 조성물
|
WO2014026125A1
(en)
|
2012-08-10 |
2014-02-13 |
Incyte Corporation |
Pyrazine derivatives as fgfr inhibitors
|
DK2904406T3
(en)
|
2012-10-04 |
2018-06-18 |
Vertex Pharma |
METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE
|
WO2014062604A1
(en)
|
2012-10-16 |
2014-04-24 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
HUE037371T2
(hu)
|
2012-12-07 |
2018-08-28 |
Vertex Pharma |
2-Amino-6-fluor-N-(5-fluor-4-(4-(4-(oxetan-3-il)piperazin-1-karbonil)piperidin-1-il)piridin-3-il) pirazolo[1,5alfa]pirimidin-3-karboxamid mint ATR kináz inhibitor
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
TWI498325B
(zh)
*
|
2013-01-18 |
2015-09-01 |
Hoffmann La Roche |
3-取代吡唑及其用途
|
WO2014114928A1
(en)
|
2013-01-23 |
2014-07-31 |
Astrazeneca Ab |
Chemical compounds
|
JP6200520B2
(ja)
*
|
2013-02-02 |
2017-09-20 |
正大天晴薬業集団股▲ふん▼有限公司 |
置換2−アミノピリジンプロテインキナーゼ阻害剤
|
EP2970311A4
(de)
|
2013-03-14 |
2016-11-23 |
Brigham & Womens Hospital |
Bmp-hemmer und verfahren zur verwendung davon
|
JP2016512815A
(ja)
|
2013-03-15 |
2016-05-09 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
Atrキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体
|
CN109776525B
(zh)
|
2013-04-19 |
2022-01-21 |
因赛特控股公司 |
作为fgfr抑制剂的双环杂环
|
JP6527513B2
(ja)
|
2013-11-20 |
2019-06-05 |
シグナルケム・ライフサイエンシーズ・コーポレイションSignalchem Lifesciences Corporation |
Tamファミリーキナーゼ阻害剤としてのキナゾリン誘導体
|
MX2016006815A
(es)
|
2013-11-27 |
2016-12-02 |
Signalchem Lifesciences Corp |
Derivados de aminopiridina como inhibidores de cinasas de la familia de tyro3, axl y mer (tam).
|
AU2014360380B2
(en)
|
2013-12-06 |
2019-03-21 |
Vertex Pharmaceuticals Incorporated |
2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as ATR kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
|
JP2017514793A
(ja)
*
|
2014-03-26 |
2017-06-08 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. |
Bmp阻害用組成物及びbmp阻害方法
|
WO2015162456A1
(en)
|
2014-04-24 |
2015-10-29 |
Novartis Ag |
Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
|
JP6433509B2
(ja)
|
2014-04-24 |
2018-12-05 |
ノバルティス アーゲー |
ホスファチジルイノシトール3−キナーゼ阻害薬としてのアミノピラジン誘導体
|
BR112016023967A2
(pt)
*
|
2014-04-24 |
2017-08-15 |
Novartis Ag |
derivados de pirazina como inibidores de fosfatidilinositol 3-cinase
|
SG11201610197XA
(en)
|
2014-06-05 |
2017-01-27 |
Vertex Pharma |
Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
|
PL3157566T3
(pl)
|
2014-06-17 |
2019-10-31 |
Vertex Pharma |
Metoda leczenia nowotworu przy użyciu kombinacji inhibitorów chk1 i atr
|
TWI723572B
(zh)
|
2014-07-07 |
2021-04-01 |
日商第一三共股份有限公司 |
具有四氫吡喃基甲基之吡啶酮衍生物及其用途
|
WO2016011019A1
(en)
|
2014-07-15 |
2016-01-21 |
The Brigham And Women's Hospital, Inc. |
Compositions and methods for inhibiting bmp
|
US9359336B2
(en)
|
2014-10-09 |
2016-06-07 |
Allergan, Inc. |
Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
TR201815071T4
(tr)
*
|
2014-12-02 |
2018-11-21 |
Bayer Cropscience Ag |
Zararlılarla mücadele maddesi olarak bisiklik bileşikler.
|
WO2016091891A1
(en)
|
2014-12-09 |
2016-06-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Human monoclonal antibodies against axl
|
US9580423B2
(en)
|
2015-02-20 |
2017-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
AU2016219822B2
(en)
|
2015-02-20 |
2020-07-09 |
Incyte Holdings Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
WO2016135041A1
(en)
|
2015-02-26 |
2016-09-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Fusion proteins and antibodies comprising thereof for promoting apoptosis
|
US9840503B2
(en)
|
2015-05-11 |
2017-12-12 |
Incyte Corporation |
Heterocyclic compounds and uses thereof
|
ES2928684T3
(es)
*
|
2015-06-25 |
2022-11-21 |
Taiho Pharmaceutical Co Ltd |
Agente terapéutico para la fibrosis
|
US9708333B2
(en)
|
2015-08-12 |
2017-07-18 |
Incyte Corporation |
Fused bicyclic 1,2,4-triazine compounds as TAM inhibitors
|
WO2017035366A1
(en)
|
2015-08-26 |
2017-03-02 |
Incyte Corporation |
Pyrrolopyrimidine derivatives as tam inhibitors
|
WO2017059357A1
(en)
|
2015-09-30 |
2017-04-06 |
Vertex Pharmaceuticals Incorporated |
Method for treating cancer using a combination of dna damaging agents and atr inhibitors
|
TW201718581A
(zh)
|
2015-10-19 |
2017-06-01 |
英塞特公司 |
作為免疫調節劑之雜環化合物
|
LT3377488T
(lt)
*
|
2015-11-19 |
2023-01-10 |
Incyte Corporation |
Heterocikliniai junginiai, kaip imunomoduliatoriai
|
SI3394033T1
(sl)
|
2015-12-22 |
2021-03-31 |
Incyte Corporation |
Heterociklične spojine kot imunomodulatorji
|
WO2017146236A1
(ja)
|
2016-02-26 |
2017-08-31 |
小野薬品工業株式会社 |
Axl阻害剤と免疫チェックポイント阻害剤とを組み合わせて投与することを特徴とする癌治療のための医薬
|
TWI753892B
(zh)
|
2016-03-28 |
2022-02-01 |
美商英塞特公司 |
作為tam抑制劑之吡咯并三嗪化合物
|
MA44860A
(fr)
|
2016-05-06 |
2019-03-13 |
Incyte Holdings Corp |
Composés hétérocycliques utilisés comme immunomodulateurs
|
WO2017205464A1
(en)
|
2016-05-26 |
2017-11-30 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
EP4137489A1
(de)
|
2016-06-20 |
2023-02-22 |
Incyte Corporation |
Heterocyclische verbindungen als immunmodulatoren
|
WO2018013789A1
(en)
|
2016-07-14 |
2018-01-18 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
EP3504198B1
(de)
|
2016-08-29 |
2023-01-25 |
Incyte Corporation |
Heterocyclische verbindungen als immunmodulatoren
|
KR102279347B1
(ko)
*
|
2016-12-15 |
2021-07-21 |
한국생명공학연구원 |
피리딘계 화합물을 유효성분으로 함유하는 dyrk 관련 질환의 예방 또는 치료용 약학적 조성물
|
WO2018111049A1
(ko)
*
|
2016-12-15 |
2018-06-21 |
한국생명공학연구원 |
피리딘계 화합물을 유효성분으로 함유하는 dyrk 관련 질환의 예방 또는 치료용 약학적 조성물
|
MX2019007416A
(es)
|
2016-12-22 |
2019-12-11 |
Incyte Corp |
Derivados de benzooxazol como inmunomoduladores.
|
ES2874756T3
(es)
|
2016-12-22 |
2021-11-05 |
Incyte Corp |
Derivados de triazolo[1,5-A]piridina como inmunomoduladores
|
US20180179179A1
(en)
|
2016-12-22 |
2018-06-28 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
CN110312511B
(zh)
|
2017-02-15 |
2023-10-27 |
大鹏药品工业株式会社 |
医药组合物
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
WO2019039525A1
(ja)
|
2017-08-23 |
2019-02-28 |
小野薬品工業株式会社 |
Axl阻害剤を有効成分として含むがん治療剤
|
MX2020003375A
(es)
|
2017-09-27 |
2020-08-03 |
Incyte Corp |
Sales de inhibidores de macrofagos asociados a tumores (tam).
|
US11826363B2
(en)
|
2017-10-13 |
2023-11-28 |
Ono Pharmaceutical Co., Ltd. |
Therapeutic agent for solid cancers, which comprises Axl inhibitor as active ingredient
|
BR112020022392A2
(pt)
|
2018-05-04 |
2021-02-02 |
Incyte Corporation |
formas sólidas de um inibidor de fgfr e processos para preparação das mesmas
|
MX2020011639A
(es)
|
2018-05-04 |
2021-02-15 |
Incyte Corp |
Sales de un inhibidor de receptores de factor de crecimiento de fibroblastos (fgfr).
|
HRP20230306T1
(hr)
|
2018-05-11 |
2023-05-12 |
Incyte Corporation |
Derivati tetrahidro-imidazo[4,5-c]piridina kao pd-l1 imunomodulatori
|
TWI832871B
(zh)
|
2018-06-29 |
2024-02-21 |
美商英塞特公司 |
Axl/mer 抑制劑之調配物
|
WO2020185532A1
(en)
|
2019-03-08 |
2020-09-17 |
Incyte Corporation |
Methods of treating cancer with an fgfr inhibitor
|
KR102200032B1
(ko)
*
|
2019-03-13 |
2021-01-08 |
전남대학교산학협력단 |
호흡기 질환의 예방 또는 치료용 조성물
|
US11591329B2
(en)
|
2019-07-09 |
2023-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
CA3150434A1
(en)
|
2019-08-09 |
2021-02-18 |
Incyte Corporation |
Salts of a pd-1/pd-l1 inhibitor
|
TW202126652A
(zh)
|
2019-09-30 |
2021-07-16 |
美商英塞特公司 |
作為免疫調節劑之吡啶并[3,2—d]嘧啶化合物
|
IL291901A
(en)
|
2019-10-14 |
2022-06-01 |
Incyte Corp |
Bicyclyl heterocycles as fgr suppressors
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
KR20220101664A
(ko)
|
2019-11-11 |
2022-07-19 |
인사이트 코포레이션 |
Pd-1/pd-l1 억제제의 염 및 결정질 형태
|
WO2021113479A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
KR20220131900A
(ko)
|
2019-12-04 |
2022-09-29 |
인사이트 코포레이션 |
Fgfr 억제제의 유도체
|
WO2021146424A1
(en)
|
2020-01-15 |
2021-07-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
WO2022099018A1
(en)
|
2020-11-06 |
2022-05-12 |
Incyte Corporation |
Process of preparing a pd-1/pd-l1 inhibitor
|
US11760756B2
(en)
|
2020-11-06 |
2023-09-19 |
Incyte Corporation |
Crystalline form of a PD-1/PD-L1 inhibitor
|
US11866434B2
(en)
|
2020-11-06 |
2024-01-09 |
Incyte Corporation |
Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
|
CA3215903A1
(en)
|
2021-04-12 |
2022-10-20 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
|
EP4352059A1
(de)
|
2021-06-09 |
2024-04-17 |
Incyte Corporation |
Tricyclische heterocyclen als fgfr-inhibitoren
|